LabCorp obtiene la aprobación de la FDA para pruebas conjuntas de Covid-19 que aumentan la capacidad y ahorran suministros

Seeking to improve turnaround times for Covid-19 testing, Burlington-based LabCorp (NYSE: LH) has received emergency approval from the U.S. Food and Drug Administration to conduct group testing.

Whether due to increased demand or a diminishing supply of testing reagents, the ability to test multiple samples at one time creates efficiencies.

The matrixed, pooled testing method received Emergency Use Authorization from the FDA on July 24.

Essentially, up to five samples can be tested at once, with the ability to isolate and identify a positive sample through patterns detected robotically.

“We believe science and technology are the best ways to beat the virus, and our matrixed pooled testing method is another way LabCorp is helping to respond to this health crisis,” said Brian Caveney, chief medical officer and president of LabCorp Diagnostics.

So-called hot spots, particularly in the Southeast, Texas and California, have seen surges in the number of confirmed cases, putting increased pressure on testing.

Pooled testing can cut down on the number of tests needed across specific populations. While a negative result is not definitive, weeding out those who do not need further testing can help ensure those who do need individual testing to confirm infection can receive a test.

“Pooling methods test groups of individuals efficiently and with high quality, while increasing our overall testing capacity. The demand for testing continues to increase and we are committed to finding innovative solutions to ensure testing is available,” Caveney said.

Fuente del artículo original: Diario de negocios triangular